Related references
Note: Only part of the references are listed.Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders
Celine Kaegi et al.
FRONTIERS IN IMMUNOLOGY (2022)
Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders
Celine Kaegi et al.
ALLERGY (2021)
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases
Giulio Cavalli et al.
AUTOIMMUNITY REVIEWS (2021)
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis
Allan L. Klein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
Claudia Kedor et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
Lars Fugger et al.
CELL (2020)
Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
Celine Kaegi et al.
FRONTIERS IN IMMUNOLOGY (2020)
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
Seza Ozen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Molecular Mimicry and Uveitis
Gerhild Wildner et al.
FRONTIERS IN IMMUNOLOGY (2020)
Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach
Peter A. Nigrovic et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Structural Basis of IL-1 Family Cytokine Signaling
James K. Fields et al.
FRONTIERS IN IMMUNOLOGY (2019)
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Celine Kaegi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial
Carly A. Janssen et al.
RHEUMATOLOGY (2019)
Anakinra in the Treatment of Patients with Refractory Scleritis: A Pilot Study
C. Bottin et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2018)
Cryopyrin-associated periodic syndrome in early childhood can be successfully treated with interleukin-1 blockades
Vesa Eskola et al.
ACTA PAEDIATRICA (2018)
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study
Theodora Kanni et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
F. De Benedetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Use of Gevokizumab in Patients with Behcet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study
Ilknur Tugal-Tutkun et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2018)
A phase I study of anti-inflammatory therapy with rilonacept in adolescents and adults with type 1 diabetes mellitus
Perrin C. White et al.
PEDIATRIC DIABETES (2018)
Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome
Dorota M. Rowczenio et al.
BLOOD (2018)
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
Nicolino Ruperto et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study
Karoline Krause et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Anakinra for Colchicine-Resistant Familial Mediterranean Fever A Randomized, Double-Blind, Placebo-Controlled Trial
Ilan Ben-Zvi et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist
Megha Garg et al.
JCI INSIGHT (2017)
Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study
Peter C. Grayson et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Immune regulation by glucocorticoids
Derek W. Cain et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Interleukin-1 antagonism in type 1 diabetes of long duration
E. Seelig et al.
DIABETES & METABOLISM (2016)
Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence The AIRTRIP Randomized Clinical Trial
Antonio Brucato et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
Torbjorn Kullenberg et al.
RHEUMATOLOGY (2016)
Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa A Randomized Clinical Trial
Vassiliki Tzanetakou et al.
JAMA DERMATOLOGY (2016)
Canakinumab in adults with steroid-refractory pyoderma gangrenosum
A. G. A. Kolios et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
An overview of FDA-approved biologics medicines
Michael S. Kinch
DRUG DISCOVERY TODAY (2015)
Anakinra treatment in drug-resistant Behcet's disease: a case series
Luca Cantarini et al.
CLINICAL RHEUMATOLOGY (2015)
Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behcet's Disease: A Case Series
Antonio Vitale et al.
DERMATOLOGY (2014)
Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study
John S. Sundy et al.
JOURNAL OF RHEUMATOLOGY (2014)
Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Norman T. Ilowite et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Long-Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic Arthritis
Daniel J. Lovell et al.
ARTHRITIS AND RHEUMATISM (2013)
Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study
Karoline Krause et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial
Essack Mitha et al.
RHEUMATOLOGY (2013)
Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens
Jasmin B. Kuemmerle-Deschner et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator
Robert A. Terkeltaub et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study
K. Krause et al.
ALLERGY (2012)
Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever A Randomized Trial
Philip J. Hashkes et al.
ANNALS OF INTERNAL MEDICINE (2012)
IL-1 Trap rilonacept in refractory adult onset Still's disease
Olga Petryna et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
Naomi Schlesinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Anakinra treatment of SAPHO syndrome: short-term results of an open study
Daniel Wendling et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial
H. Ralph Schumacher et al.
ARTHRITIS AND RHEUMATISM (2012)
Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes
Cailin H. Sibley et al.
ARTHRITIS AND RHEUMATISM (2012)
Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study
Dan Nordstrom et al.
JOURNAL OF RHEUMATOLOGY (2012)
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Nicolino Ruperto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Interleukin-1 Inhibition and Fatigue in Primary Sjogren's Syndrome - A Double Blind, Randomised Clinical Trial
Katrine Braekke Norheim et al.
PLOS ONE (2012)
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study
H. Ralph Schumacher et al.
ARTHRITIS CARE & RESEARCH (2012)
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
Pierre Quartier et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
Naomi Schlesinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
On-demand anakinra treatment is effective in mevalonate kinase deficiency
E. J. Bodar et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Efficacy and Safety of Anakinra Therapy in Pediatric and Adult Patients With the Autoinflammatory Muckle-Wells Syndrome
Jasmin B. Kuemmerle-Deschner et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
Rieke Alten et al.
BMC MUSCULOSKELETAL DISORDERS (2011)
Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis
Jun Bao et al.
CLINICAL RHEUMATOLOGY (2011)
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1 beta-mediated diseases
Alexander M. Owyang et al.
MABS (2011)
Genetics of monogenic autoinflammatory diseases: past successes, future challenges
Ivona Aksentijevich et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature
J. T. Gran et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2011)
Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
Isabelle Kone-Paut et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study
Naomi Schlesinger et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Canakinumab for the Treatment of Acute Flares in Difficult-to-Treat Gouty Arthritis Results of a Multicenter, Phase II, Dose-Ranging Study
Alexander So et al.
ARTHRITIS AND RHEUMATISM (2010)
An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)
Norma Jung et al.
CLINICAL RHEUMATOLOGY (2010)
Follow-Up and Quality of Life of Patients with Cryopyrin-Associated Periodic Syndromes Treated with Anakinra
Loredana Lepore et al.
JOURNAL OF PEDIATRICS (2010)
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study
Norman Ilowite et al.
CLINICAL RHEUMATOLOGY (2009)
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Helen J. Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome
M. Gattorno et al.
ARTHRITIS AND RHEUMATISM (2008)
Efficacy and safety of rilonacept (Interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes
Hal M. Hoffman et al.
ARTHRITIS AND RHEUMATISM (2008)
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
R. M. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Beneficial response to anakinra and thalidomide in Schnitzler's syndrome
HD de Koning et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
MC Genovese et al.
ARTHRITIS AND RHEUMATISM (2004)
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate
SB Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis - A large, international, multicenter, placebo-controlled trial
RM Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2003)
Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation
JH Antin et al.
BLOOD (2002)
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis
G Nuki et al.
ARTHRITIS AND RHEUMATISM (2002)
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
S Cohen et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
